Vallerie McLaughlin, MD, explains why the ERS update strongly recommends sotatercept for patients with pulmonary arterial hypertension (PAH) who don't reach low-risk status on initial therapy.
|Articles|July 30, 2021
Pharmacy Clinical Pearl of the Day: Lipophilic Statins vs Hydrophilic Statins
Author(s)Saro Arakelians, PharmD
Lipophilic statins for dyslipidemia penetrate muscle more easily than hydrophilic statins and are associated with a higher incidence of adverse effects.
Advertisement
List of statins for dyslipidemia and lipophilic versus hydrophilic treatments:
- Fluvastatin (Lescol)
- Lovastatin (Mevacor, Altoprev)
- Pravastatin (Pravachol)
- Simvastatin (Zocor)
- Atorvastatin (Lipitor)
- Rosuvastatin (Crestor)
- Pitavastatin (Livalo)
Explanation:
- Myalgia may be related to lipophilicity (fat loving) and to high dosage, as well as interaction with other medications.
- Lipophilic statins penetrate muscle more easily than hydrophilic statins and are associated with a higher incidence of adverse effects, particularly myopathy, although reports of muscle toxicity, including rhabdomyolysis, have been reported with all statins.
- Hydrophilic statins stay out of muscle and brain tissue, which are fat filled.
Reference
Advertisement
Related to this article
HYPERION trial data now support sotatercept within a patient's first year of pulmonary arterial hypertension (PAH) diagnosis, cutting clinical worsening risk by 76% compared with placebo.
A stewardship program combining EHR alerts and pharmacist-led education offers a replicable model for reducing bleeding risk.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
Isatuximab plus Iberdomide maintenance helps MRD-positive myeloma patients turn MRD-negative after transplant, with manageable safety.
Insulin efsitora alfa-gobe (Onswik; Eli Lilly and Company) is designed to deliver steady basal insulin levels over a full 7-day duration.
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Belzutifan Plus Lenvatinib for Advanced Renal Cell Carcinoma After Immunotherapy
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
4
FDA Approves Insulin Efsitora, Once-Weekly Basal Insulin Injection for Adults With T2D
5